Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
A closer look at the risk of major adverse events, severe hypoglycemia, and all-cause mortality for commonly used therapies in treating type 2 diabetes.
Read More »Examining the Risks of Antihyperglycemic Dual and Triple Therapies for T2D
New CV Outcomes Trials Examine Linagliptin and Glimepiride Among Patients With High CVD Risk
The CAROLINA and CARMELINA Trials offer further information regarding the CV safety of linagliptin and glimepiride among patients with T2DM, high CVD risk, and decreased renal function.
Read More »Sulfonylureas’ Association with Major Adverse Effects
After almost 50 years, is the age of sulfonylureas coming to an end?
Read More »Metformin vs. Sulfonylurea To Lower Dementia Risk In T2D
A recent study found important effects on dementia in African American patients with type 2 diabetes
Read More »Which Oral Meds Are Best At Reducing HbA1c?
Data from this study shows the effects of oral diabetes medications on HbA1C levels from two separate cohort groups.
Read More »Pioglitazone or Sulfonylureas in Patients with Pretreatment Cardiovascular Risk
Cardiovascular risks in patients with type 2 diabetes using sulfonylureas vs. pioglitazone: personalized care approach.
Read More »Optimizing Diabetes Care: A More Personalized Patient-Centered Approach
Which baseline clinical characteristics of patients with newly diagnosed diabetes lead us to providing more personalized care?
Read More »People with Type 2 at Risk with Use of Sulfonylureas as Second-Line Medication
Drugs shown to increase risk of hypoglycemic and cardiovascular events.
Read More »Sulfonylureas and the Risk of Cardiovascular and Hypoglycemia Events
Even as 2nd-line drugs, sulfonylureas shown to be cardiotoxic with high rate of low blood glucose
Read More »Sulfonylureas No More!
Cheapest treatment associated with increased risks of cardiovascular events and death.
Read More »